SEARCH

SEARCH BY CITATION

Pharmacotherapy for obesity inline image

  1. Top of page
  2. Pharmacotherapy for obesity inline image
  3. Recent progress in the genetics of common obesity inline image
  4. Obesity treatment: novel peripheral targets inline image
  5. Rise in antiobesity drug prescribing for children and adolescents in the UK: a population-based study inline image
  6. New central targets for the treatment of obesity inline image
  7. Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders inline image
  8. Metformin increases plasma ghrelin in Type 2 diabetes inline image
  9. Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers inline image
  10. Effect of efavirenz on high-density lipoprotein antioxidant properties in HIV-infected patients inline image
  11. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide inline image
  12. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype inline image
  13. Relationship between blood alcohol concentration on admission and outcome in dimethoate organophosphorus self-poisoning inline image
  14. Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase inline image
  15. Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A inline image
  16. Potentially inappropriate prescribing in an Irish elderly population in primary care inline image
  17. Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study inline image
  18. Exposure to folic acid antagonists during the first trimester of pregnancy and the risk of major malformations inline image

Mingfang Li & Bernard M. Y. Cheung

inline image

Recent progress in the genetics of common obesity inline image

  1. Top of page
  2. Pharmacotherapy for obesity inline image
  3. Recent progress in the genetics of common obesity inline image
  4. Obesity treatment: novel peripheral targets inline image
  5. Rise in antiobesity drug prescribing for children and adolescents in the UK: a population-based study inline image
  6. New central targets for the treatment of obesity inline image
  7. Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders inline image
  8. Metformin increases plasma ghrelin in Type 2 diabetes inline image
  9. Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers inline image
  10. Effect of efavirenz on high-density lipoprotein antioxidant properties in HIV-infected patients inline image
  11. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide inline image
  12. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype inline image
  13. Relationship between blood alcohol concentration on admission and outcome in dimethoate organophosphorus self-poisoning inline image
  14. Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase inline image
  15. Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A inline image
  16. Potentially inappropriate prescribing in an Irish elderly population in primary care inline image
  17. Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study inline image
  18. Exposure to folic acid antagonists during the first trimester of pregnancy and the risk of major malformations inline image

Ruth J. F. Loos

inline image

Obesity treatment: novel peripheral targets inline image

  1. Top of page
  2. Pharmacotherapy for obesity inline image
  3. Recent progress in the genetics of common obesity inline image
  4. Obesity treatment: novel peripheral targets inline image
  5. Rise in antiobesity drug prescribing for children and adolescents in the UK: a population-based study inline image
  6. New central targets for the treatment of obesity inline image
  7. Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders inline image
  8. Metformin increases plasma ghrelin in Type 2 diabetes inline image
  9. Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers inline image
  10. Effect of efavirenz on high-density lipoprotein antioxidant properties in HIV-infected patients inline image
  11. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide inline image
  12. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype inline image
  13. Relationship between blood alcohol concentration on admission and outcome in dimethoate organophosphorus self-poisoning inline image
  14. Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase inline image
  15. Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A inline image
  16. Potentially inappropriate prescribing in an Irish elderly population in primary care inline image
  17. Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study inline image
  18. Exposure to folic acid antagonists during the first trimester of pregnancy and the risk of major malformations inline image

Benjamin C. T. Field, Owais B. Chaudhri & Stephen R. Bloom

inline image

Rise in antiobesity drug prescribing for children and adolescents in the UK: a population-based study inline image

  1. Top of page
  2. Pharmacotherapy for obesity inline image
  3. Recent progress in the genetics of common obesity inline image
  4. Obesity treatment: novel peripheral targets inline image
  5. Rise in antiobesity drug prescribing for children and adolescents in the UK: a population-based study inline image
  6. New central targets for the treatment of obesity inline image
  7. Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders inline image
  8. Metformin increases plasma ghrelin in Type 2 diabetes inline image
  9. Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers inline image
  10. Effect of efavirenz on high-density lipoprotein antioxidant properties in HIV-infected patients inline image
  11. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide inline image
  12. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype inline image
  13. Relationship between blood alcohol concentration on admission and outcome in dimethoate organophosphorus self-poisoning inline image
  14. Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase inline image
  15. Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A inline image
  16. Potentially inappropriate prescribing in an Irish elderly population in primary care inline image
  17. Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study inline image
  18. Exposure to folic acid antagonists during the first trimester of pregnancy and the risk of major malformations inline image

Russell M. Viner, Yingfen Hsia, Antje Neubert & Ian C. K. Wong

inline image

New central targets for the treatment of obesity inline image

  1. Top of page
  2. Pharmacotherapy for obesity inline image
  3. Recent progress in the genetics of common obesity inline image
  4. Obesity treatment: novel peripheral targets inline image
  5. Rise in antiobesity drug prescribing for children and adolescents in the UK: a population-based study inline image
  6. New central targets for the treatment of obesity inline image
  7. Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders inline image
  8. Metformin increases plasma ghrelin in Type 2 diabetes inline image
  9. Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers inline image
  10. Effect of efavirenz on high-density lipoprotein antioxidant properties in HIV-infected patients inline image
  11. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide inline image
  12. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype inline image
  13. Relationship between blood alcohol concentration on admission and outcome in dimethoate organophosphorus self-poisoning inline image
  14. Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase inline image
  15. Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A inline image
  16. Potentially inappropriate prescribing in an Irish elderly population in primary care inline image
  17. Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study inline image
  18. Exposure to folic acid antagonists during the first trimester of pregnancy and the risk of major malformations inline image

Bruce J. Sargent & Nicholas A. Moore

inline image

Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders inline image

  1. Top of page
  2. Pharmacotherapy for obesity inline image
  3. Recent progress in the genetics of common obesity inline image
  4. Obesity treatment: novel peripheral targets inline image
  5. Rise in antiobesity drug prescribing for children and adolescents in the UK: a population-based study inline image
  6. New central targets for the treatment of obesity inline image
  7. Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders inline image
  8. Metformin increases plasma ghrelin in Type 2 diabetes inline image
  9. Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers inline image
  10. Effect of efavirenz on high-density lipoprotein antioxidant properties in HIV-infected patients inline image
  11. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide inline image
  12. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype inline image
  13. Relationship between blood alcohol concentration on admission and outcome in dimethoate organophosphorus self-poisoning inline image
  14. Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase inline image
  15. Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A inline image
  16. Potentially inappropriate prescribing in an Irish elderly population in primary care inline image
  17. Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study inline image
  18. Exposure to folic acid antagonists during the first trimester of pregnancy and the risk of major malformations inline image

David J. Heal, Jane Gosden & Sharon L. Smith

inline image

Metformin increases plasma ghrelin in Type 2 diabetes inline image

  1. Top of page
  2. Pharmacotherapy for obesity inline image
  3. Recent progress in the genetics of common obesity inline image
  4. Obesity treatment: novel peripheral targets inline image
  5. Rise in antiobesity drug prescribing for children and adolescents in the UK: a population-based study inline image
  6. New central targets for the treatment of obesity inline image
  7. Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders inline image
  8. Metformin increases plasma ghrelin in Type 2 diabetes inline image
  9. Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers inline image
  10. Effect of efavirenz on high-density lipoprotein antioxidant properties in HIV-infected patients inline image
  11. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide inline image
  12. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype inline image
  13. Relationship between blood alcohol concentration on admission and outcome in dimethoate organophosphorus self-poisoning inline image
  14. Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase inline image
  15. Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A inline image
  16. Potentially inappropriate prescribing in an Irish elderly population in primary care inline image
  17. Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study inline image
  18. Exposure to folic acid antagonists during the first trimester of pregnancy and the risk of major malformations inline image

Matthew P. Doogue, Evan J. Begg, M. Peter Moore, Helen Lunt, Chris J. Pemberton & Mei Zhang

inline image

Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers inline image

  1. Top of page
  2. Pharmacotherapy for obesity inline image
  3. Recent progress in the genetics of common obesity inline image
  4. Obesity treatment: novel peripheral targets inline image
  5. Rise in antiobesity drug prescribing for children and adolescents in the UK: a population-based study inline image
  6. New central targets for the treatment of obesity inline image
  7. Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders inline image
  8. Metformin increases plasma ghrelin in Type 2 diabetes inline image
  9. Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers inline image
  10. Effect of efavirenz on high-density lipoprotein antioxidant properties in HIV-infected patients inline image
  11. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide inline image
  12. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype inline image
  13. Relationship between blood alcohol concentration on admission and outcome in dimethoate organophosphorus self-poisoning inline image
  14. Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase inline image
  15. Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A inline image
  16. Potentially inappropriate prescribing in an Irish elderly population in primary care inline image
  17. Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study inline image
  18. Exposure to folic acid antagonists during the first trimester of pregnancy and the risk of major malformations inline image

Kyoung Soo Lim, Joo-Youn Cho, Bo-Hyung Kim, Jung-Ryul Kim, Hwa-Sook Kim, Dong-Kyu Kim, Sung-Ho Kim, Hyeon Joo Yim, Sung-Hack Lee, Sang-Goo Shin, In-Jin Jang & Kyung-Sang Yu

inline image

Effect of efavirenz on high-density lipoprotein antioxidant properties in HIV-infected patients inline image

  1. Top of page
  2. Pharmacotherapy for obesity inline image
  3. Recent progress in the genetics of common obesity inline image
  4. Obesity treatment: novel peripheral targets inline image
  5. Rise in antiobesity drug prescribing for children and adolescents in the UK: a population-based study inline image
  6. New central targets for the treatment of obesity inline image
  7. Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders inline image
  8. Metformin increases plasma ghrelin in Type 2 diabetes inline image
  9. Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers inline image
  10. Effect of efavirenz on high-density lipoprotein antioxidant properties in HIV-infected patients inline image
  11. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide inline image
  12. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype inline image
  13. Relationship between blood alcohol concentration on admission and outcome in dimethoate organophosphorus self-poisoning inline image
  14. Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase inline image
  15. Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A inline image
  16. Potentially inappropriate prescribing in an Irish elderly population in primary care inline image
  17. Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study inline image
  18. Exposure to folic acid antagonists during the first trimester of pregnancy and the risk of major malformations inline image

S. A. Pereira, J. R. Batuca, U. Caixas, T. Branco, J. Delgado-Alves, I. Germano, F. Lampreia & E. C. Monteiro

inline image

Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide inline image

  1. Top of page
  2. Pharmacotherapy for obesity inline image
  3. Recent progress in the genetics of common obesity inline image
  4. Obesity treatment: novel peripheral targets inline image
  5. Rise in antiobesity drug prescribing for children and adolescents in the UK: a population-based study inline image
  6. New central targets for the treatment of obesity inline image
  7. Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders inline image
  8. Metformin increases plasma ghrelin in Type 2 diabetes inline image
  9. Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers inline image
  10. Effect of efavirenz on high-density lipoprotein antioxidant properties in HIV-infected patients inline image
  11. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide inline image
  12. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype inline image
  13. Relationship between blood alcohol concentration on admission and outcome in dimethoate organophosphorus self-poisoning inline image
  14. Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase inline image
  15. Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A inline image
  16. Potentially inappropriate prescribing in an Irish elderly population in primary care inline image
  17. Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study inline image
  18. Exposure to folic acid antagonists during the first trimester of pregnancy and the risk of major malformations inline image

Lisbeth V. Jacobsen, Charlotte Hindsberger, Richard Robson & Milan Zdravkovic

inline image

Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype inline image

  1. Top of page
  2. Pharmacotherapy for obesity inline image
  3. Recent progress in the genetics of common obesity inline image
  4. Obesity treatment: novel peripheral targets inline image
  5. Rise in antiobesity drug prescribing for children and adolescents in the UK: a population-based study inline image
  6. New central targets for the treatment of obesity inline image
  7. Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders inline image
  8. Metformin increases plasma ghrelin in Type 2 diabetes inline image
  9. Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers inline image
  10. Effect of efavirenz on high-density lipoprotein antioxidant properties in HIV-infected patients inline image
  11. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide inline image
  12. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype inline image
  13. Relationship between blood alcohol concentration on admission and outcome in dimethoate organophosphorus self-poisoning inline image
  14. Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase inline image
  15. Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A inline image
  16. Potentially inappropriate prescribing in an Irish elderly population in primary care inline image
  17. Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study inline image
  18. Exposure to folic acid antagonists during the first trimester of pregnancy and the risk of major malformations inline image

Ina Scholz, Heike Oberwittler, Klaus-Dieter Riedel, Jürgen Burhenne, Johanna Weiss, Walter E. Haefeli & Gerd Mikus

inline image

Relationship between blood alcohol concentration on admission and outcome in dimethoate organophosphorus self-poisoning inline image

  1. Top of page
  2. Pharmacotherapy for obesity inline image
  3. Recent progress in the genetics of common obesity inline image
  4. Obesity treatment: novel peripheral targets inline image
  5. Rise in antiobesity drug prescribing for children and adolescents in the UK: a population-based study inline image
  6. New central targets for the treatment of obesity inline image
  7. Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders inline image
  8. Metformin increases plasma ghrelin in Type 2 diabetes inline image
  9. Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers inline image
  10. Effect of efavirenz on high-density lipoprotein antioxidant properties in HIV-infected patients inline image
  11. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide inline image
  12. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype inline image
  13. Relationship between blood alcohol concentration on admission and outcome in dimethoate organophosphorus self-poisoning inline image
  14. Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase inline image
  15. Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A inline image
  16. Potentially inappropriate prescribing in an Irish elderly population in primary care inline image
  17. Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study inline image
  18. Exposure to folic acid antagonists during the first trimester of pregnancy and the risk of major malformations inline image

Michael Eddleston, David Gunnell, Ludwig von Meyer & Peter Eyer

inline image

Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase inline image

  1. Top of page
  2. Pharmacotherapy for obesity inline image
  3. Recent progress in the genetics of common obesity inline image
  4. Obesity treatment: novel peripheral targets inline image
  5. Rise in antiobesity drug prescribing for children and adolescents in the UK: a population-based study inline image
  6. New central targets for the treatment of obesity inline image
  7. Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders inline image
  8. Metformin increases plasma ghrelin in Type 2 diabetes inline image
  9. Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers inline image
  10. Effect of efavirenz on high-density lipoprotein antioxidant properties in HIV-infected patients inline image
  11. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide inline image
  12. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype inline image
  13. Relationship between blood alcohol concentration on admission and outcome in dimethoate organophosphorus self-poisoning inline image
  14. Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase inline image
  15. Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A inline image
  16. Potentially inappropriate prescribing in an Irish elderly population in primary care inline image
  17. Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study inline image
  18. Exposure to folic acid antagonists during the first trimester of pregnancy and the risk of major malformations inline image

David J. Greenblatt, Diane E. Peters, Lauren E. Oleson, Jerold S. Harmatz, Malcolm W. MacNab, Noah Berkowitz, Miguel A. Zinny & Michael H. Court

inline image

Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A inline image

  1. Top of page
  2. Pharmacotherapy for obesity inline image
  3. Recent progress in the genetics of common obesity inline image
  4. Obesity treatment: novel peripheral targets inline image
  5. Rise in antiobesity drug prescribing for children and adolescents in the UK: a population-based study inline image
  6. New central targets for the treatment of obesity inline image
  7. Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders inline image
  8. Metformin increases plasma ghrelin in Type 2 diabetes inline image
  9. Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers inline image
  10. Effect of efavirenz on high-density lipoprotein antioxidant properties in HIV-infected patients inline image
  11. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide inline image
  12. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype inline image
  13. Relationship between blood alcohol concentration on admission and outcome in dimethoate organophosphorus self-poisoning inline image
  14. Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase inline image
  15. Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A inline image
  16. Potentially inappropriate prescribing in an Irish elderly population in primary care inline image
  17. Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study inline image
  18. Exposure to folic acid antagonists during the first trimester of pregnancy and the risk of major malformations inline image

Sandrine Turpault, William Brian, Robert Van Horn, Alix Santoni, Franck Poitiers, Yves Donazzolo & Xavier Boulenc

inline image

Potentially inappropriate prescribing in an Irish elderly population in primary care inline image

  1. Top of page
  2. Pharmacotherapy for obesity inline image
  3. Recent progress in the genetics of common obesity inline image
  4. Obesity treatment: novel peripheral targets inline image
  5. Rise in antiobesity drug prescribing for children and adolescents in the UK: a population-based study inline image
  6. New central targets for the treatment of obesity inline image
  7. Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders inline image
  8. Metformin increases plasma ghrelin in Type 2 diabetes inline image
  9. Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers inline image
  10. Effect of efavirenz on high-density lipoprotein antioxidant properties in HIV-infected patients inline image
  11. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide inline image
  12. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype inline image
  13. Relationship between blood alcohol concentration on admission and outcome in dimethoate organophosphorus self-poisoning inline image
  14. Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase inline image
  15. Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A inline image
  16. Potentially inappropriate prescribing in an Irish elderly population in primary care inline image
  17. Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study inline image
  18. Exposure to folic acid antagonists during the first trimester of pregnancy and the risk of major malformations inline image

Cristín Ryan, Denis O’Mahony, Julia Kennedy, Peter Weedle & Stephen Byrne

inline image

Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study inline image

  1. Top of page
  2. Pharmacotherapy for obesity inline image
  3. Recent progress in the genetics of common obesity inline image
  4. Obesity treatment: novel peripheral targets inline image
  5. Rise in antiobesity drug prescribing for children and adolescents in the UK: a population-based study inline image
  6. New central targets for the treatment of obesity inline image
  7. Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders inline image
  8. Metformin increases plasma ghrelin in Type 2 diabetes inline image
  9. Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers inline image
  10. Effect of efavirenz on high-density lipoprotein antioxidant properties in HIV-infected patients inline image
  11. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide inline image
  12. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype inline image
  13. Relationship between blood alcohol concentration on admission and outcome in dimethoate organophosphorus self-poisoning inline image
  14. Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase inline image
  15. Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A inline image
  16. Potentially inappropriate prescribing in an Irish elderly population in primary care inline image
  17. Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study inline image
  18. Exposure to folic acid antagonists during the first trimester of pregnancy and the risk of major malformations inline image

Maurice Beghetti, Sheila G. Haworth, Damien Bonnet, Robyn J. Barst, Philippe Acar, Alain Fraisse, Dunbar D. Ivy, Xavier Jais, Ingram Schulze-Neick, Nazzareno Galiè, Adele Morganti, Jasper Dingemanse, Andjela Kusic-Pajic & Rolf M. F. Berger

inline image

Exposure to folic acid antagonists during the first trimester of pregnancy and the risk of major malformations inline image

  1. Top of page
  2. Pharmacotherapy for obesity inline image
  3. Recent progress in the genetics of common obesity inline image
  4. Obesity treatment: novel peripheral targets inline image
  5. Rise in antiobesity drug prescribing for children and adolescents in the UK: a population-based study inline image
  6. New central targets for the treatment of obesity inline image
  7. Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders inline image
  8. Metformin increases plasma ghrelin in Type 2 diabetes inline image
  9. Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers inline image
  10. Effect of efavirenz on high-density lipoprotein antioxidant properties in HIV-infected patients inline image
  11. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide inline image
  12. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype inline image
  13. Relationship between blood alcohol concentration on admission and outcome in dimethoate organophosphorus self-poisoning inline image
  14. Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase inline image
  15. Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A inline image
  16. Potentially inappropriate prescribing in an Irish elderly population in primary care inline image
  17. Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study inline image
  18. Exposure to folic acid antagonists during the first trimester of pregnancy and the risk of major malformations inline image

Ilan Matok, Rafael Gorodischer, Gideon Koren, Daniella Landau, Arnon Wiznitzer & Amalia Levy

inline image